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1. Introduction
Based on the number of new cases of cancer in humans each year, hepatocellular carcinoma
(HCC) is the sixth most common cancer worldwide [20], the fifth in males and the seventh
in females [37]. In the most recently reported year, 748,000 new cases of the tumour were
recorded, constituting 9.2% of all new cancers [20]. Furthermore, the number of new cases of
the tumour continues to increase year by year. Not only is HCC common, it also carries an
especially grave prognosis, ranking third in annual cancer mortality rates. In the year men‐
tioned, the total death rate from the tumour was 695,900. Of the patients who died, 93% did
so within 12 months of the onset of symptoms. This 12 month fatality ratio in HCC (0.93 -
0.96) is the highest of any human tumour.
HCC does not have a uniform geographical distribution. Rather, of all the new cases of the
cancer recorded during recent years, approximately 84% occurred in resource-constrained
(developing) countries [20], particularly in sub-Saharan Africa and the Asia Pacific region.
In these regions the dominant cause of HCC is chronic hepatitis B virus (HBV) infection.
This infection is almost invariably acquired very early in life, either as a result of perinatal
transmission of the virus or of horizontal transmission in infancy or early childhood, times
at which the infection very often becomes chronic [42]. The tumour resulting from the HBV
infection frequently occurs at a young or relatively young age, and it carries a particularly
grave prognosis.
In addition to chronic HBV infection, the other major cause of HCC in these high-risk re‐
gions is dietary exposure to aflatoxins, the toxic secondary metabolites of the fungi, Aspergil‐
lus flavus and Aspergillus parasiticus. These viral and fungal risk factors are largely
responsible for the striking geographical variation in incidence of HCC. Both aflatoxin expo‐
sure and chronic HBV infection are more common in rural than in urban dwellers in re‐
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source-constrained regions [42, 63]. In these regions, the association between aflatoxin
exposure and the development of HCC is closest in sub-Saharan Africa [51].
Aflatoxins are structurally-related difuranocoumarin derivatives, some of which are muta‐
genic and carcinogenic in humans and animals [89, 87]. These toxins are widely distributed
in nature. Because atmospheric humidity and moisture content of plants are important fac‐
tors in determining growth of, and toxin production by, these moulds, contamination of
crops occurs mainly in tropical and sub-tropical climates with high humidity and tempera‐
ture. These conditions exist in sub-Saharan Africa, the Asia Pacific region, and parts of
South America. Contamination is particularly likely to occur in subsistence farming com‐
munities in regions with these climates and where regulations to control exposure to the
fungi are either non-existent or unenforceable in practice.
In these regions, the moulds contaminate a variety of staple foods, especially maize and
groundnuts [89, 34, 87]. Because most rural dwellers can afford only limited food variation,
these staples make up a significant portion of their diets. Contamination of crops with afla‐
toxins occurs either during their growth or as a result of their storage under conditions that
promote fungal growth and toxin production [31, 32, 33]. Exposure begins in utero as a result
of trans-placental transmission of the toxins [86] and in the postnatal period as a result of
breast-feeding [85], and continues throughout life. Exposure increases with increasing age -
for example, in Malaysia evidence of exposure was more common in the population aged 31
to 50 years than that aged 18 to 30 years [46].
Approximately 4.5 billion of the world’s population are believed to be exposed to aflatoxins
[88]. Between 25,200 new cases of HCC each year (or 4.6% of all cases of the tumour world‐
wide) and 155,000 new cases each year (or 28.2% of all cases of the tumour world wide) may
be attributed to this exposure [51]. It has been estimated that aflatoxins play a causative role
in at least 4.6% and at most 28.2% of all cases of HCC worldwide [51]. These large ranges
stem from the considerable uncertainty and variability in data on cancer potency factors,
HBV prevalence, aflatoxin exposure, and other risk factors [51].
Although the parent aflatoxin molecule is harmless, it is converted by members of the cyto‐
chrome 450 superfamily into electrophilic intermediates that are mutagenic and carcinogen‐
ic [90, 87, 40, 71]. Of the four naturally occurring aflatoxins, aflatoxin B1 (AFB1), B2, G1 and
G2, toxigenic strains of A. flavus typically produce only aflatoxins B1 and B2, whereas most
strains of A. parasiticus produce all of the aflatoxins [18]. AFB1 is the most potent experimen‐
tal hepatocarcinogen known to man -- no animal model exposed to the toxin thus far has
failed to develop HCC. AFM1, the hydroxylation product of AFB1, is found in milk and milk
products when animals intended for dairy production consume aflatoxin-contaminated feed
[70]. In rodents exposed to AFB1 in equivalent doses to those occurring in humans, levels of
aflatoxin adduct in the serum have correlated with levels of hepatic DNA damage and with
development of HCC [83].
AFB1 is the aflatoxin most often found in contaminated human foodstuffs [78], and exposure
to AFB1 is causally related to the development of HCC in humans [34]. The correlation be‐
tween the degree of exposure to AFB1 and the incidence of HCC is direct. It has been estimat‐
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ed that by reducing dietary AFB1 levels to below detectable limits in Asia and sub-Saharan
Africa, between 72,800 and 98,800 new cases of HCC could be prevented each year [49].
The major human cytochrome P450 (CYP) enzymes involved in aflatoxin metabolism are
CYP3A4, 3A5, 3A7 and 1A2, and the predominant site of metabolism is the liver [87, 39].
AFB1 is metabolized to an AFB1-8,9-exo-epoxide and, to a lesser extent, an AFB1-8,9-endo-ep‐
oxide. The exo-epoxide binds to DNA to form the predominant promutagenic 8,9-dihydro-8-
(N7-guanyl)-9-hydroxy AFB1 (AFB1-N7-Gua) adduct. AFB1-N7-Gua can result in two
secondary forms, an apurinic site and a more stable ring-opened AFB1-formamidopyrimi‐
dine (AFB1-FABY) adduct, which is far more persistent in vivo. This adduct causes G to T
transversion mutations [28, 4, 87], the most prevalent of which are targeted to the site of the
original adduct. AFB1-FABY exists as a mixture of two rotameric forms. In Escherichia coli
AFB1-FABY induced a six-fold higher G to T mutation frequency than AFB1-N7-Gua, with
mutations also occurring adjacent to the site of adduct formation [82]. AFB1-FABY also re‐
sulted in blocked replication. Subsequent studies showed that the form of AFB1-FABY nor‐
mally present in double-stranded DNA is mutagenic, whereas the dominant species in
single-stranded DNA blocks replication [5].
Chronic liver injury and regenerative hyperplasia are critical to the development of HCC
[30]. AFB1-induced DNA adducts may therefore be fixed as mutations consequent to an
HBV-related increase in cell proliferation and hyperplasia. Inflammation and oxidative
stress associated with chronic active hepatitis and aflatoxin exposure may also result direct‐
ly in DNA damage and mutations [52].
The ‘DNA damage checkpoint response’ acts as an anti-tumour mechanism against genotox‐
ic agents. By playing a central role in co-ordinating DNA repair and cell cycle progression,
‘DNA damage checkpoint response’ proteins play a key role in preventing mutations [66].
Genotoxic doses of AFB1 induce an incomplete and inefficient ‘DNA damage checkpoint re‐
sponse’, which may contribute to the carcinogenic properties of the toxin [27].
AFB1 has a geographical distribution similar to that of chronic HBV infection, colonizing a
variety of foodstuffs in the same Far Eastern and sub-Saharan African countries. According‐
ly, a synergistic interaction between the hepatocarcinogenic effects of HBV and AFB1 would
offer a plausible explanation for the very high incidence of HCC, and perhaps also the
young age of the patients, in these regions.
2. Evidence for a synergistic hepatocarcinogenic interaction between
aflatoxins and hepatitis B virus
Although a study in Guanxi, China published in the mid-1980s showed that HCC occurring
in individuals infected with HBV who lived in villages with a “high” consumption of afla‐
toxins had a mortality rate that was 10 times higher than that in individuals living in vil‐
lages with a “low” consumption [93], other early studies of the consequences of exposure to
aflatoxins did not include data on the HBV status of the populations studied. All of these
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studies showed a statistically significant increase in incidence of HCC in those individuals
who were exposed to the fungal toxin [31, 53, 32]. But, given the high frequency of chronic
HBV infection in this region at that time, the probability exists that at least some, and possi‐
bly a significant number, of the subjects included in these early studies were also chronically
infected with HBV and that the virus, rather than the exposure to aflatoxins, could have
caused the malignant transformation or, at least, contributed to it. In two studies, one earlier
and the other later, the roles of AFB1 and HBV in explaining the varying frequencies of HCC
in different areas of Swaziland in southern Africa [61] and in Guanxi Province in China [93]
were assessed. Both analyses concluded that with simultaneous exposure to the two poten‐
tial carcinogenic agents, AFB1 exposure was the more important determinant of geographi‐
cal variation in the incidence of HCC than was HBV infection, at least in those regions.
However, no attempt was made in either study to evaluate a possible interactive hepatocar‐
cinogenic effect between the two risk factors.
The first published evidence consistent with synergism between AFB1 and HBV in the gene‐
sis of HCC was provided by experiments in which transgenic mice over-expressing the large
envelope polypeptide of HBV were fed AFB1. These mice produced more rapid and exten‐
sive hepatocyte dysplasia than did their unexposed littermates, and HCCs developed [67].
Shortly thereafter, further experimental evidence for a positive interaction between AFB1
and another member of the Hepadnaviridae family, the woodchuck hepatitis virus, in the de‐
velopment of HCC was presented [3]. Woodchucks infected with woodchuck hepatitis virus
and exposed to AFB1 developed, after six to 26 months of exposure, a high incidence of pre‐
neoplastic foci of altered hepatocytes followed by hepatocellular adenomas and HCCs.
Moreover, woodchucks infected with woodchuck hepatitis virus had earlier been shown to
have enhanced activation of the biologically inactive AFB1 to AFB1-8,9-epoxide [17]. The de‐
velopment of liver tumours was also reported in ducks infected with duck hepatitis virus
and exposed to AFB1 [14] and in tree shrews (Tupaia belangeri chinensis) infected with HBV
and exposed to AFB1 [48].
Following the introduction of methods to measure aflatoxin metabolites and aflatoxin-DNA
adducts in urine and aflatoxin-albumin adducts in serum, biomarkers that were a far more
accurate and reliable indicator of AFB1 exposure than the hitherto used food sampling and
dietary questionnaires, five large cohort studies were undertaken in Shanghai and Qidong
county, China and in Taiwan to assess the carcinogenic effects of AFB1 and HBV alone and
in combination. In four of the studies an hepatocarcinogenic effect of AFB1 alone was
shown, with increased odds ratios ranging from 1.9 to 32.0 with a mean ratio of 13.7 [65, 64,
54, 59] (Table 1). These studies proved that exposure to AFB1 alone could cause malignant
transformation of hepatocytes in humans. The fifth study failed to show an increased odds
ratio of AFB1 exposure alone [79].
As expected, these studies (including the one that did not show an increased odds ratio for
the development of HCC for AFB1 alone [79]) confirmed an hepatocarcinogenic effect of
HBV alone - odds ratios ranged from 3.3 to 17.4, with a mean ratio of 10.0 (Table 1).
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HBV alone AFB1 alone HBV and AFB1
RR (95% CL)* RR (95% CL) RR (5% CL)
[65] 4.8 (1.2 -19.7) 1.9 (0.5 - 7.5) 60.1 (6.4 - 561.8)
[64] 7.3 (2.2 - 24.4) 3.4 (1.1 - 10.0) 59.4 (15.6 - 212)
[80] 17.4 (3.6 – 143.4)
425.4)
0.3 (0 - 3.6) 70.0 (11.5 –
[54] 17.0 (2.8 - 103.9) 17.4 (3.4 - 90.3) 67.6 (12.2 - 373.2)
[59] 3.3 (1.3 - 8.3) 32.0 (4.0 - 255.8) 40.7 (12.7- 130.9)
Table 1. Findings in five studies comparing the risk of HBV infection alone, dietary exposure to AFB1 alone, and the
two risk factors together in the genesis of HCC. * Relative risk (95% confidence limits).
A synergistic interaction between AFB1 exposure and chronic HBV infection in causing HCC
was evident in each of the five studies - odds ratios ranged from 40.7 to 70.0 with a mean of
59.6 (Table 1). In three of these studies there was a striking multiplicative effect, and in the
other two a sub-multiplicative effect between exposure to AFB1 alone and exposure to AFB1
in the presence of chronic HBV infection in inducing HCC, in comparison with each carcino‐
gen alone. The study which did not show an increased odds ratio with AFB1 alone had the
highest odds ratios for both HBV infection alone and for co-existing AFB1 exposure and
HBV infection [79]. The finding in this study that exposure to AFB1 alone did not increase
the risk of HCC development [79] could conceivably be the source of the erroneous view
held by some hepatologists and oncologists that AFB1 alone does not cause HCC and is im‐
portant only as a co-carcinogen with HBV.
In other investigations, also in countries with high rates of contamination of foodstuffs by
AFB1, only individuals chronically infected with HBV were studied and the influence of
AFB1 exposure in further increasing their risk of HCC development was analysed. In Qi‐
dong county, China, over a 10-year prospective follow-up period, the risk of HCC in male
carriers of the virus was shown to be increased 3-fold (95% confidence limits 1.2, 8.7) in
those with detectable urinary levels of AFB1 metabolites in comparison with those without
these metabolites [72]. This result was later confirmed in a longer follow-up of the same co‐
hort of HBV carriers, when the risk of HCC was increased 3.5-fold (95% confidence limits
1.5, 8.1) [57]. A dose-response relationship between urinary AFB1 metabolites and the risk of
HCC was shown in HBV carriers in Taiwan [94]. Comparing high and low urinary levels of
the aflatoxin metabolite, AFM1, a multivariate-adjusted odds ratio of 6.0 (95% confidence
limits1.2, 29) was calculated. The risk was greater (odds ratio 10.0: 95% confidence limits
1.6 ; 60.9) when both AFM1 and AFB1-N7- gua metabolites were tested for and detected in
the urine. In another study performed in chronic carriers of HBV in the same country, a stat‐
istically significant relationship was noted between detectable levels of AFB1 adducts in se‐
rum and the risk of HCC, with an age-adjusted odds ratio of 2.0 (95% confidence limits 1.1,
3.7) [73]. A recent meta-analysis has shown that the population attributable risk of develop‐
ing HCC in individuals exposed to dietary aflatoxins is 17%, with the risk being 21% in
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those individuals also chronically infected with HBV [49]. Individuals infected with HBV
alone have a population attributable risk of 8.8% [49]. If the one study in the meta-analysis
that contributed most to heterogeneity in the analysis was excluded, the summarised odds
ratio of HCC (with 95% confidence limits) was 73 (36 to 148.3) for the combined effects of
AFB1 and HBV, 11.3 (6.75 to 18.9) for HBV alone, and 6.37 (3.74 to 10.86) for AFB1 alone [49].
The effect of a synergistic interaction between AFB1 and HBV on the age of onset of HCC
was specifically addressed in a study of Taiwanese patients. HBV-infected patients in whom
tumour tissue was shown by histochemical staining to be positive for AFB1-N7-gua adducts
were on average 10 years younger than those with adduct-negative tumours [10].
Although they have had limitations, various animal models with natural hepatitis viral in‐
fections have been used to examine the interaction between hepadnaviruses and AFB1 [84].
In woodchucks and tree shrews, animal species with hepadnaviral-induced liver pathology
similar to that observed in HBV-infected humans, the administration of AFB1 resulted in a
higher incidence of liver tumours than in infected animals not receiving AFB1 [92, 3]. More‐
over, HBsAg transgenic mice over-expressing the large envelope protein of HBsAg in the
liver developed HCC when exposed to aflatoxin, whereas their littermates not exposed to
carcinogens did not [67, 47].
In those human populations in which an interaction between the fungal toxin and HBV has
been described, the infection is predominantly acquired in infancy or early childhood. Dur‐
ing the early years of HBV infection, a state of immune tolerance towards the virus exists
and little if any cellular damage occurs. With loss of this tolerance, the ongoing infection re‐
sults in recurring cell damage. Exposure to AFB1 in contaminated foodstuffs also occurs in
young children [81].
Nevertheless, it is likely, certainly in China and Taiwan, where perinatal transmission of
HBV is the predominant mode of infection, and also probably in Africa, where slightly later
horizontal infection is the major route of infection, that the HBV carrier state is established,
not before exposure to, but before heavy exposure to the toxin.
3. Possible mechanisms of interaction between AFB1 and HBV in
hepatocarcinogenesis
A number of possible mechanisms for the interaction between HBV and AFB1 in causing HCC
have been suggested. One is that HBV infection directly or indirectly sensitizes hepatocytes
to the carcinogenic effects of AFB1. One way in which this may be accomplished is that the
specific cytochrome P450s that metabolize AFB1 to AFB1-8,9-epoxide may be induced either
by chronic hepatitis caused by HBV infection or by the presence of the virus itself. Induc‐
tion of these phase I enzymes has been described in HBV transgenic mice [21, 6], where this
effect appeared to result from hepatocyte injury induced by the virus rather than the pres‐
ence of the virus per se [6]. The observation that Gambian and Taiwanese children and adoles‐
cents chronically infected with HBV have higher concentrations of AFB1 adducts than uninfected
individuals [2, 76, 11] is consistent with this mechanism. But studies in adults in China, Taiwan
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and The Gambia have either failed to show a significant difference in serum AFB1 adduct
levels between HBsAg-positive and -negative subjects [23, 79, 12] or showed only a margin‐
ally significant difference [74]. Moreover, a study in woodchucks with chronic woodchuck
hepatitis virus infection did not show enhanced activation of AFB1 [75, 44].
The generated aflatoxin-8,9-epoxide has been shown to bind to proteins, causing acute toxic‐
ity, or to DNA inducing changes that over time increase the risk of malignant transforma‐
tion [26]. DNA damage can also increase the chance of integration of the viral DNA into the
host genome [16]. This effect could be exerted directly by AFB1 or indirectly by oxidative
stress induced by chronic viral hepatitis.
A guanine to thymine transversion at the third base of codon 249 of the p53 tumour sup‐
pressor gene (arginine to serine substitution; 249ser, R249S) is present in between 40 and 66%
of HCC patients in regions with heavy dietary exposure to AFB1 [28, 4, 45, 30]. The mutation
is also detectable in circulating cell-free DNA from the plasma of HCC patients and healthy
subjects from these regions [77]. The exact timing of the development of the 249ser mutation
remains uncertain, although it has been shown to be an early event. The mutation abrogates
the normal functions of p53, including those in cell cycle control, DNA repair, and apopto‐
sis, thereby contributing to the multistep process of hepatocarcinogenesis. This mutation is
extremely uncommon in tumors other than HCC [58].
A specific and close association between this inactivating mutation, the presence of AFB1
biomarkers, and the development of HCC was recognised in epidemiological studies in re‐
gions with high or low AFB1 exposure rates [4, 60, 15, 19, 45, 30, 62, 22], and evidence that
the mutation induced chromosomal instability was found [62]. Arising from the observation
of the co-existence of the p53 mutation and AFB1 exposure, the presence of the 249ser muta‐
tion was believed to be a primary genetic event in hepatocarcinogenesis. It occurs early in
the series of events leading to AFB1-associated HCC, and may thus provide an early bio‐
marker of exposure to the fungal toxin and AFB1-induced hepatocarcinogenesis [36].
But the findings have been inconsistent with support for an aetiological association being
provided by some but not all studies. In an investigation of Taiwanese patients with HCC
the mutation was present in 36.3% of HBV-infected patients with HCC, compared with
11.7% of those without HBV markers [79]. In a second analysis in Taiwan, all of the 249ser
mutations occurred in patients positive for HBsAg, giving an odds ratio of 10.0 (95% confi‐
dence limits 1.6; 17.5) [54]. In a study in The Gambia patients positive for HBsAg alone had
an increased relative risk of 10, those with 249ser mutation alone of13, and those with both an
estimated risk of 399 [45]. Other studies, however, showed a similar, but not a statistically
significant trend [68, 19], and in yet other analyses from a variety of countries no association
could be found [listed in reference: 69]. Furthermore, in a meta-analysis of 49 published
studies using a method that takes into account both within-study and study-to-study varia‐
bility, little evidence for HBV-AFB1 interaction in modulating the 249ser mutation was found
[69]. In addition, the absence of the 249ser mutation from the serum of patients from coun‐
tries with a low incidence of HBV-induced HCC to date suggests that chronic HBV infection
alone is insufficient to result in the development of the 249ser mutation [82].
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Another suggested possibility is that the activity of phase II detoxification enzymes (gluta‐
thione S transferase (GST) and epoxide hydrolase(EPHX)) may play a role in the genesis of
HCC induced jointly by AFB1 and HBV [94; 73; 56]. A multiplicative interaction in the gene‐
sis of HCC in West African and Chinese patients was demonstrated between HBV infection
and mutations of EPHX [56]: patients with chronic HBV infection but with normal EPHX al‐
leles were at a 15-fold increase in risk, and those with both HBV infection and at least one
EPHX mutant were at a 77-fold increased risk. In further studies in these patients a positive
interaction between HBV and AFB1 seemed to depend on the presence of a polymorphism of
the GST M1, GST T1, and EPHX genes that are normally responsible for converting the car‐
cinogenic AFB1 -8,9-epoxide to non-reactive metabolites [56, 8, 94, 73]. But again no consis‐
tent pattern has emerged. In one analysis in Taiwan the risk of HCC formation was greater
in HBV carriers who had the GST M1 null genotype compared with the non-null genotype
[94], in a second study the risk appeared to depend on the presence of a GST T1 null geno‐
type [73], and in a third the risk was considerably greater in those with null genotypes of
both GST M1 and GST T1 [8].
Another possible mechanism for a carcinogenic interaction between AFB1 and HBV is that
increased hepatocyte necrosis and proliferation cause by chronic HBV infection increases the
likelihood of both AFB1 mutations, including 249ser, and the subsequent clonal expansion of
cells containing these mutations [13]. Chronic necroinflammatory hepatic disease, including
that resulting from HBV infection, results in the generation of oxygen and nitrogen reactive
species [50, 35]. Both of the latter are mutagenic, but, in addition, increased oxidative stress
has been shown to induce 249ser mutations [29].
The HBV x gene is frequently included in sequences of the virus that are integrated into cel‐
lular DNA [43]. AFB1-DNA adducts are normally repaired by the nucleotide excision repair
pathway. The HBV X protein interferes with the nuclear excision repair pathway [38; 43]
and might, by this means, favour persistence of existing mutations or impaired DNA. DNA
repair is also compromised by the rapid cell turnover rate in chronic hepatitis. In the pres‐
ence of dietary exposure to AFB1, the HB X protein may contribute to the uncontrolled cell
proliferation in other ways. The transcription of p21 waf1/ cip1, which induces cell cycle arrest at
the G1-S checkpoint, is activated by HB X protein in a dose-dependent manner in the pres‐
ence of functional p53. This transcription is, however, repressed by HB X protein when p53
is not functional or is functional at a low level [1]. The expression of HB X protein also corre‐
lates with an increase in the overall frequency of DNA mutations in transgenic mice and a 2-
fold increase the incidence of the 249ser mutation in transgenic mice exposed to AFB1 [55].
Altered methylation of genes may play a role in hepatocarcinogenesis [43]. For example, the
methylation status of the human ras association domain gene (RASSF1A) and the P16 gene
has been incriminated in the pathogenesis of HCC [95]. No association was found between
methylation status and P53 status {95]. A statistically significant association was, however,
found between RASSF1A methylation status and the level of AFB1-DNA adducts in HCC
tissues [95].
An understanding of the mechanisms responsible for the heightened risk of malignant
transformation in patients chronically infected with HBV and exposed to AFB1 is far from
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complete, and there is clearly a need for further research to be undertaken into the pathoge‐
netic mechanisms involved in this interaction between the two common hepatocarcinogens
in resource-constrained geographical regions.
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